Ozempic and Your Brain: What They Aren’t Telling You

#Ozempic #GLP1 #BrainHealth #WeightLoss #obesitymedicine A physician breaks down what Ozempic really does to your brain — benefits, risks, and what the science actually shows.🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter📚 The Weight Equation & The Physician’s PhysiquePhysician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.https://www.drmohammedpaika.com/books👥 Metabolic Health CommunityLive Q&As, evidence-based education, accountability, workouts, nutrition guidance & community support.https://www.skool.com/metabolic-health-community-5316TIMESTAMPS 00:00 Intro — What Ozempic Really Does to Your Brain00:54 Who This Is For (and Who I Am)01:49 How GLP-1 Drugs Talk to Your Brain03:34 The Whole-Body Domino Effect04:43 The Immune System Gets a Reset05:57 Neuroprotection: BDNF, Amyloid & Tau07:31 Does This Prevent Dementia? The Evidence, Ranked12:05 Addiction Circuitry: Alcohol, Nicotine & Dopamine15:40 Psychotic Disorders: Why Not Much Is Expected16:28 Mood & Anxiety (+ the Jan 2026 FDA Update)19:02 Eating Disorders: Binge Eating & Bulimia21:13 Cardiovascular & Stroke Protection23:22 The Full Picture24:38 What to Do NextReferences1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/2. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). NEJM, 2023. https://pubmed.ncbi.nlm.nih.gov/37952131/3. Rhea EM, Banks WA. Obesity-induced blood-brain barrier dysfunction: phenotypes and mechanisms. J Neuroinflammation, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11056074/4. GLP-1 programs the neurovascular landscape. Cell Metabolism, 2024. https://www.cell.com/cell-metabolism/fulltext/S1550-4131(24)00367-X5. Efficacy and safety of oral semaglutide in early-stage symptomatic Alzheimer's disease (EVOKE/EVOKE+ trials). The Lancet, 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00459-9/fulltext6. Wang W, et al. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimer's & Dementia, 2024. https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.143137. Wang W, Volkow ND, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in a real-world population. Nature Communications, 2024. https://www.nature.com/articles/s41467-024-48780-68. Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 2025. https://pubmed.ncbi.nlm.nih.gov/39937469/9. Once-weekly semaglutide vs. placebo in alcohol use disorder and comorbid obesity: RCT. The Lancet, 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00305-3/fulltext10. Volkow ND, Xu R. GLP-1R agonist medications for addiction treatment. Addiction, 2025. https://onlinelibrary.wiley.com/doi/10.1111/add.1662611. FDA Drug Safety Communication: FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RA Medications. Jan 13, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp12. EMA review finds no link between GLP-1 receptor agonists and suicidal thoughts. April 2024. https://pharmaceutical-journal.com/article/news/ema-finds-no-link-between-glp-1-receptor-agonists-and-suicidal-thoughts13. Richards J, et al. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study. Obesity Pillars, 2023. https://www.sciencedirect.com/science/article/pii/S266736812300026814. Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity, 2016. https://pubmed.ncbi.nlm.nih.gov/27136388/⚕️ MEDICAL & EDUCATIONAL DISCLAIMER⚕️ MEDICAL & EDUCATIONAL DISCLAIMERThis content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship with Dr. Mohammed K. Paika. Always consult your healthcare provider before making changes to medications, diet, exercise, or weight-loss treatment, including GLP-1 therapies. Individual risks and results vary